Related Experiment Video
Updated: Jun 25, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion
Meng Hu1, Congying Zhong1, Jiabing Wang1
1Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Abstract:
Recently, targeted therapy and immunotherapy have emerged as effective treatment options for non-small cell lung cancer (NSCLC). This progress has been facilitated by the rapid development of diagnostic and therapeutic technologies and the continuous research and development of new drugs, leading to a new era in precision medicine for NSCLC. This is a breakthrough for patients with common mutations in the human epidermal growth factor receptor (EGFR) gene in NSCLC. Consequently, the use of targeted drugs has significantly improved survival. Nevertheless, certain rare genetic mutations are referred to as EGFR exon 20 insertion (ex20ins) mutations, which differ in structure from conventional EGFR gene mutations, namely, exon 19 deletion mutations (19-Del) and exon 21 point mutations. Owing to their distinct structural characteristics, patients harboring these EGFR ex20ins mutations are unresponsive to traditional tyrosine kinase inhibitor (TKI) therapy. This particular group of patients did not fall within the scope of their applicability. However, the activating A763_Y764insFQEA mutation elicits a more pronounced response than mutations in the near and far regions of the C-helix immediately following it and should, therefore, be treated differently. Currently, there is a lack of effective treatments for EGFR ex20ins mutations NSCLC. The efficacy of chemotherapy has been relatively favorable, whereas the effectiveness of immunotherapy remains ambiguous owing to inadequate clinical data. In addition, the efficacy of the first- and second-generation targeted drugs remains limited. However, third-generation and novel targeted drugs have proven to be effective. Although novel EGFR-TKIs are expected to treat EGFR ex20ins mutations in patients with NSCLC, they face many challenges. The main focus of this review is on emerging therapies that target NSCLC with EGFR ex20ins and highlight major ongoing clinical trials while also providing an overview of the associated challenges and research advancements in this area.
Insights
New targeted therapies show promise for non-small cell lung cancer (NSCLC) patients with rare EGFR exon 20 insertion mutations. These emerging treatments offer hope where traditional therapies failed, addressing a critical unmet need in precision medicine.
Area of Science:
- Oncology
- Molecular Biology
- Precision Medicine
Background:
- Non-small cell lung cancer (NSCLC) treatment has advanced with targeted therapy and immunotherapy, particularly for common EGFR mutations.
- EGFR exon 20 insertion (ex20ins) mutations present unique structural challenges, rendering them unresponsive to traditional tyrosine kinase inhibitors (TKIs).
- A significant unmet need exists for effective treatments for NSCLC patients with EGFR ex20ins mutations.
Purpose of the Study:
- To review emerging therapies targeting NSCLC with EGFR ex20ins mutations.
- To highlight ongoing clinical trials and recent research advancements in this area.
- To discuss the challenges associated with developing novel treatments for this patient population.
Main Methods:
- Literature review focusing on recent advancements in targeted therapy and immunotherapy for NSCLC.
- Analysis of clinical trial data for novel EGFR-TKIs and other emerging treatment modalities.
- Discussion of the structural characteristics of EGFR ex20ins mutations and their impact on treatment response.
Main Results:
- First- and second-generation targeted drugs show limited efficacy against EGFR ex20ins mutations.
- Third-generation and novel targeted drugs, including novel EGFR-TKIs, demonstrate promising efficacy.
- Chemotherapy offers relatively favorable outcomes, while immunotherapy's effectiveness remains under investigation due to limited data.
Conclusions:
- Novel targeted therapies, particularly novel EGFR-TKIs, represent a significant advancement in treating NSCLC with EGFR ex20ins mutations.
- Despite progress, challenges remain in optimizing treatment strategies and overcoming resistance mechanisms.
- Continued research and clinical trials are crucial to fully realize the potential of emerging therapies for this patient group.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...